Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts. more
Time Frame | GUTS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.46% | -3.35% | -2.97% |
1-Month Return | -16.89% | -3.49% | -0.66% |
3-Month Return | -33.09% | -12.6% | 2.71% |
6-Month Return | -66.04% | -6.91% | 7.21% |
1-Year Return | -87.87% | 1.19% | 23.04% |
Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 120.00K | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Cost of Revenue | 893.00K | 770.00K | 676.00K | 452.00K | 77.00K | [{"date":"2019-09-30","value":100,"profit":true},{"date":"2020-09-30","value":86.23,"profit":true},{"date":"2021-09-30","value":75.7,"profit":true},{"date":"2022-09-30","value":50.62,"profit":true},{"date":"2023-09-30","value":8.62,"profit":true}] |
Gross Profit | (893.00K) | (770.00K) | (676.00K) | (452.00K) | 43.00K | [{"date":"2019-09-30","value":-2076.74,"profit":false},{"date":"2020-09-30","value":-1790.7,"profit":false},{"date":"2021-09-30","value":-1572.09,"profit":false},{"date":"2022-09-30","value":-1051.16,"profit":false},{"date":"2023-09-30","value":100,"profit":true}] |
Gross Margin | - | - | - | - | 35.83% | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Operating Expenses | 29.03M | 28.19M | 36.25M | 48.93M | 50.88M | [{"date":"2019-09-30","value":57.05,"profit":true},{"date":"2020-09-30","value":55.41,"profit":true},{"date":"2021-09-30","value":71.25,"profit":true},{"date":"2022-09-30","value":96.18,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Operating Income | (29.92M) | (28.96M) | (36.93M) | (49.38M) | (50.84M) | [{"date":"2019-09-30","value":-2991900000,"profit":false},{"date":"2020-09-30","value":-2896100000,"profit":false},{"date":"2021-09-30","value":-3692800000,"profit":false},{"date":"2022-09-30","value":-4938500000,"profit":false},{"date":"2023-09-30","value":-5083600000,"profit":false}] |
Total Non-Operating Income/Expense | - | (3.02M) | (3.25M) | 3.73M | (25.00M) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":-81.04,"profit":false},{"date":"2021-09-30","value":-87.13,"profit":false},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":-670.29,"profit":false}] |
Pre-Tax Income | (30.59M) | (30.48M) | (38.73M) | (46.45M) | (77.09M) | [{"date":"2019-09-30","value":-3059200000,"profit":false},{"date":"2020-09-30","value":-3048000000,"profit":false},{"date":"2021-09-30","value":-3873500000,"profit":false},{"date":"2022-09-30","value":-4645300000,"profit":false},{"date":"2023-09-30","value":-7709100000,"profit":false}] |
Income Taxes | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Income From Continuous Operations | - | (30.48M) | (38.73M) | (46.45M) | (77.09M) | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":-3048000000,"profit":false},{"date":"2021-09-30","value":-3873500000,"profit":false},{"date":"2022-09-30","value":-4645300000,"profit":false},{"date":"2023-09-30","value":-7709100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (30.59M) | (30.48M) | (38.73M) | (46.45M) | (77.09M) | [{"date":"2019-09-30","value":-3059200000,"profit":false},{"date":"2020-09-30","value":-3048000000,"profit":false},{"date":"2021-09-30","value":-3873500000,"profit":false},{"date":"2022-09-30","value":-4645300000,"profit":false},{"date":"2023-09-30","value":-7709100000,"profit":false}] |
EPS (Diluted) | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
GUTS | |
---|---|
Cash Ratio | 5.39 |
Current Ratio | 5.58 |
Quick Ratio | 5.57 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GUTS | |
---|---|
ROA (LTM) | -55.32% |
ROE (LTM) | -286.16% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GUTS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.60 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.40 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GUTS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 942.14 |
P/B | 1.82 |
Price/FCF | NM |
EV/R | 718.09 |
EV/Ebitda | NM |
Fractyl Health, Inc. Common Stock (GUTS) share price today is $1.82
Yes, Indians can buy shares of Fractyl Health, Inc. Common Stock (GUTS) on Vested. To buy Fractyl Health, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GUTS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Fractyl Health, Inc. Common Stock (GUTS) via the Vested app. You can start investing in Fractyl Health, Inc. Common Stock (GUTS) with a minimum investment of $1.
You can invest in shares of Fractyl Health, Inc. Common Stock (GUTS) via Vested in three simple steps:
The 52-week high price of Fractyl Health, Inc. Common Stock (GUTS) is $15. The 52-week low price of Fractyl Health, Inc. Common Stock (GUTS) is $1.74.
The price-to-earnings (P/E) ratio of Fractyl Health, Inc. Common Stock (GUTS) is
The price-to-book (P/B) ratio of Fractyl Health, Inc. Common Stock (GUTS) is 1.82
The dividend yield of Fractyl Health, Inc. Common Stock (GUTS) is 0.00%
The market capitalization of Fractyl Health, Inc. Common Stock (GUTS) is $91.39M
The stock symbol (or ticker) of Fractyl Health, Inc. Common Stock is GUTS